79,593 Edwards Lifesciences Corporation $EW Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. decreased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 13.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 531,398 shares of the medical research company’s stock after selling 79,593 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.09% of Edwards Lifesciences worth $45,870,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. NorthRock Partners LLC increased its holdings in shares of Edwards Lifesciences by 1.0% during the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock worth $1,465,000 after acquiring an additional 153 shares during the last quarter. Elevation Wealth Partners LLC raised its stake in Edwards Lifesciences by 24.8% in the 3rd quarter. Elevation Wealth Partners LLC now owns 779 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 155 shares during the period. Plan A Wealth LLC lifted its holdings in Edwards Lifesciences by 3.0% during the 3rd quarter. Plan A Wealth LLC now owns 5,460 shares of the medical research company’s stock valued at $471,000 after purchasing an additional 158 shares during the last quarter. Premier Path Wealth Partners LLC lifted its holdings in Edwards Lifesciences by 4.4% during the 1st quarter. Premier Path Wealth Partners LLC now owns 3,880 shares of the medical research company’s stock valued at $311,000 after purchasing an additional 162 shares during the last quarter. Finally, Ferguson Wellman Capital Management Inc. boosted its position in Edwards Lifesciences by 0.7% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 27,077 shares of the medical research company’s stock worth $2,168,000 after purchasing an additional 185 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on EW shares. Jefferies Financial Group upped their price objective on shares of Edwards Lifesciences from $102.00 to $105.00 and gave the company a “buy” rating in a report on Friday, July 24th. The Goldman Sachs Group raised their target price on shares of Edwards Lifesciences from $98.00 to $102.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Raymond James Financial lifted their target price on shares of Edwards Lifesciences from $100.00 to $103.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Argus upped their price target on shares of Edwards Lifesciences from $105.00 to $115.00 and gave the company a “buy” rating in a research note on Friday, August 21st. Finally, Rothschild & Co Redburn boosted their price target on Edwards Lifesciences from $99.00 to $102.00 and gave the company a “buy” rating in a research note on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Trading Up 2.0%

Shares of EW stock opened at $90.15 on Friday. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a market cap of $51.91 billion, a P/E ratio of 51.81, a price-to-earnings-growth ratio of 2.32 and a beta of 0.87. The stock has a 50 day simple moving average of $88.10 and a 200 day simple moving average of $86.60. Edwards Lifesciences Corporation has a 1 year low of $74.66 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. The company’s revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the company earned $0.67 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president directly owned 17,984 shares in the company, valued at $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 5,045 shares of company stock worth $451,596. Company insiders own 0.31% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.